Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Novo Nordisk's shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe's largest by market capitalization. Novo Nordisk's ADR (NVO) (DK:NOVO.B), at ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

Shares of Novo Nordisk NVO gained 5% on June 10, following a report that activist hedge fund Parvus Asset Management is building a stake in the company. Per the Financial Times, this London-based ...

As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as ...

Newly public Omada Health says it won't turn patient care over to AI as the tech consumes investor interest.

Could GLP-1 weight loss drugs like Ozempic and changing economic winds really take a bite out of the almighty Big Mac?

McDonald's just got McSmacked by a side of science as GLP-1 weight-loss drugs threaten to shrink not just waistlines but ...